OncoMatch/Clinical Trials/NCT04150744
RFA Plus Carrizumab vs Carrizumab Alone for HCC
Is NCT04150744 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies radiofrequency ablation for tumor immunity.
Treatment: radiofrequency ablation — The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage BCLC B, BCLC C
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: local ablation
Have local ablation...in 3 months before enrolled.
Cannot have received: TACE
Have...TACE...in 3 months before enrolled.
Cannot have received: radiotherapy
Have...radiotherapy in 3 months before enrolled.
Cannot have received: anti-tumor vaccine and other immunostimulate anti-tumor drugs
Patients have anti-tumor vaccine and other immunostimulate anti-tumor drugs in 3 months
Lab requirements
Kidney function
Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g [excluded]
Liver function
Child-Pugh Score: A or B
Cardiac function
Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia [excluded]
The function of main organs normal; Child-Pugh Score: A or B; Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g [excluded]; Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify